Immunocore Holdings plc: Bellevue Group AG amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Bellevue Group AG amended its Schedule 13G filing on Immunocore Holdings plc, disclosing a change in its passive stake in the Nasdaq-listed biotech under SEC accession 0001104659-26-128597. The filing did not specify the size or direction of the stake change in the headline disclosure. The update matters because 13G amendments signal shifts in institutional ownership that can influence Immunocore's shareholder base and governance dynamics. Investors will watch for the full filing details to confirm Bellevue's current position and whether further amendments follow.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Bellevue Group AG, Immunocore Holdings plc